Enliven Therapeutics Inc. (ELVN NASDAQ) stock market data APIs
$19.0535
-0.52(-2.7%)
as of September 17, 2025
Try our APIs with
free plan!
Enliven Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Prev. Close
19.0535
Open
18.5295
High
19.3516
Low
18.5295
52 wk Range
13.3-30.03
Market Cap
1 092 M
Shares Outstanding
59 236 K
EPS
-0.49
Beta
1.033
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Enliven Therapeutics Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enliven Therapeutics Inc. data using free add-ons & libraries
Get Enliven Therapeutics Inc. Fundamental Data
Enliven Therapeutics Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -113 926 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.55
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enliven Therapeutics Inc. News
New
What's going on in today's pre-market session
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] TODAY'S PRE-MAR...
Terns Pharmaceuticals’ SWOT analysis: obesity drug stock poised for pivotal data
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s stock has garnered si...
Enliven files automatic mixed securities shelf
* Enliven Therapeutics (NASDAQ:ELVN [https://seekingalpha.com/symbol/ELVN]) filed automatic mixed securities shelf. * Filing [https://seekingalpha.com/filing/10301128] MORE ON ENLIVEN THERAPEUTIC...
Enliven Therapeutics, Inc Q2 Loss Climbs
(RTTNews) - Enliven Therapeutics, Inc (ELVN) revealed Loss for its second quarter of -$25.34 million The company's bottom line totaled -$25.34 million, or -$0.49 per share. This compares with -$19.9...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
